BTIG Maintains Buy on RxSight, Raises Price Target to $72
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Ryan Zimmerman has maintained a Buy rating on RxSight (NASDAQ:RXST) and increased the price target from $61 to $72.
May 07, 2024 | 9:47 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BTIG analyst Ryan Zimmerman reaffirmed a Buy rating on RxSight and raised the price target from $61 to $72.
The increase in price target by a reputable analyst like Ryan Zimmerman suggests a strong confidence in RxSight's future performance. This kind of positive analyst coverage typically leads to increased investor interest and can drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100